You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

peripheral T-cell lymphomas (PTCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

PTCL Patients Who Achieved Complete Response From Frontline Treatment Trial (Selinexor)

Not yet recruiting
  • PTCL Patients Who Achieved Complete Response From Frontline Treatment
  • (no location specified)
Apr 18, 2023

Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Lymphoma
  • Brentuximab Vedotin
  • +3 more
  • Beijing, China
  • +15 more
Jan 4, 2023

Peripheral T-cell Lymphomas (PTCL) Trial in Taiwan (Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine

Not yet recruiting
  • Peripheral T-cell Lymphomas (PTCL)
  • Lenalidomide and Gemcitabine (Dose level 11)
  • +3 more
  • Kaohsiung, Taiwan
  • +3 more
Nov 1, 2021

Lymphoma, T-Cell, Peripheral Trial in Czechia (Adcetris 50 MG Injection, Endoxan, Doxorubicin)

Not yet recruiting
  • Lymphoma, T-Cell, Peripheral
  • Adcetris 50 MG Injection
  • +4 more
  • Brno, Czechia
  • +6 more
Aug 26, 2021

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

Active, not recruiting
  • Refractory T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Bari, Italy
  • +6 more
Aug 1, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Non-Hodgkin's Lymphoma (NHL), Peripheral T Cell Lymphoma (PTCL) Trial in Tianjin (Ex-vivo expanded allogeneic ?dT cells)

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • Peripheral T Cell Lymphoma (PTCL)
  • Ex-vivo expanded allogeneic γδT cells
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Disease Hospital
Jan 5, 2021

Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) Trial in United States (KT-333)

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +4 more
  • Orange, California
  • +8 more
Nov 29, 2022

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial

Not yet recruiting
  • CD5+ Relapsed/Refractory Hematopoietic Malignancies
  • +5 more
  • CT125A cells
  • Cyclophosphamide, fludarabine
  • (no location specified)
Feb 19, 2021

Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)

Not yet recruiting
  • Relapsed or Refractory T-cell Lymphomas
  • Sendai-shi, Miyagi, Japan
    Local Institution - 0001
Sep 12, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 19, 2022

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

Recruiting
  • Anaplastic Large Cell Lymphoma
  • +19 more
  • Duarte, California
  • +2 more
Aug 15, 2022

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Allo-HSCT as First-line Consolidation in High-risk PTCL

Recruiting
  • T Cell Lymphoma
    • Beijing, China
      Peking University People's Hospital
    Jul 31, 2022

    Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

    Recruiting
    • Peripheral T Cell Lymphoma
    • +2 more
    • Chidamide combined with Duvillisib
    • Xiamen, Fujian, China
      The First Affiliated Hosptial of Xiamen University
    Nov 28, 2023

    Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

    Recruiting
    • Peripheral T Cell Lymphoma
    • Azacitidine Injection
    • +6 more
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Nov 8, 2022

    Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Nivolumab and EPOCH
    • Duarte, California
    • +2 more
    Jan 6, 2023